Grant M. Gallagher

The development of BNT162 is based on BioNTech’s mRNA platform; the vaccine will then be produced using Pfizer’s vaccine manufacturing capacities.

West and Central African nations have been developing infrastructure to combat ebola, malaria, malnutrition, and more.

Heparin may lower the odds of SARS-CoV-2 infection, according to investigators from the Rensselaer Polytechnic Institute.

A modeling study from Imperial College shows the pandemic may have significant effect on mortality among other infectious disease patients.

Mylan Pharmaceuticals also announced that a batch of daptomycin has been recalled due to contamination.

Findings were announced during the special COVID-19 sessions of the virtual 23rd International AIDS Conference.

Investigators in Tanzania trialed modest, automated financial incentives for clinic attendance on viral suppression for patients initiating ART.

Investigators compared characteristics and retention between daily and event-driven PrEP patients to better understand low uptake of event-driven PrEP.

Experts assessed the impact of drug overdoses on people living with HIV in British Columbia, identifying factors associated with mortality using competing risk methodology.

People with HIV are living longer than ever at present time, raising quality of life concerns about later stage medical and psychological challenges comorbidities.

The California PrEP Assistance Program, established to remove financial and structural barriers to PrEP access, had positive but uneven initial results.

Guidelines recommend concentrated adherence counseling and frequent viral load testing for virologic failure, but drug resistance testing is often excluded.

Despite being within the age group at highest risk for severe SARS-CoV-2 infection, a recent survey suggests that the population is not inherently more willing to socially isolate.

A report released for AIDS 2020 warns the international AIDS response could be set back substantially by ongoing events.

CUSTOMIZE was designed to identify methods of implementing an experimental once-monthly, long-acting regimen antiretroviral therapy against HIV-1 into clinical practice.

. The following is a list of key recalls that may be relevant to infectious diseases, with links to full recall statements.

The European Commission has granted Marketing Authorization for a 2-dose Ebola vaccine regimen.

New recommendations are intended to aid biomedical firms in achieving licensure of a safe and effective vaccine.

Opaganib is set to be evaluated against SARS-CoV-2 in a multi-center, randomized, parallel arm, double-blind, placebo-controlled study.

“Anti-Viral Immune Enhancement” also recalled due to unsubstantiated coronavirus claims.

The infectious disease pharmaceutical and medical device pipeline is always evolving. See a round-up of our FDA drug pipeline coverage from the past week:

While smallpox may not be in headlines today, the illness (treated with tecovirimat) remains a threat.

The Hong Kong researchers used online searches to quantify public interest in mask usage.

Given research into SARS-CoV-2 is taking place at unprecedented speed, the panel of IDSA experts had to decide on current best practices using science which is still in motion.

In order to expand the potential uses of the drug against SARS-CoV-2, Gilead Sciences has announced plans to explore administration of remdesivir in an inhaled form.

Data were published using the International Symposium on Pneumococci and Pneumococcal Diseases online digital library.

In a new analysis of Guangzhou city contact tracing data, investigators examined secondary attack rates of SARS-CoV-2.

Providing oral antibiotics to people who inject drugs with infections may reduce hospital readmissions.

The technology deploys AI-based algorithms that use machine-learning to identify respiratory failure and hemodynamic instability

The US FDA is a key global regulatory authority. Here are updates from this week on the FDA pipeline, particularly concerning infectious diseases: